Patents by Inventor Günther Metz

Günther Metz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
    Patent number: 8236818
    Abstract: The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin-4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amytrophic lateral sclerosis (ALS), anxiety and depression.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: August 7, 2012
    Assignee: Santhera Pharmaceuticals (Schweiz) AG
    Inventors: Günther Metz, Holger Deppe, Ulrich Abel, Achim Feurer, Inge Ott, Sonja Nordhoff, Michael Soeberdt, Barbara Hoffmann-Enger, Philipp Weyermann, Hervé Siendt, Christian Rummey, Miroslav Terinek, Marco Henneböhle, Holger Herzner, Cesare Mondadori
  • Substituted Imidazopyridine Derivatives As Melanocortin-4 Receptor Antagonists
    Publication number: 20100093697
    Abstract: The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin-4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amytrophic lateral sclerosis (ALS), anxiety and depression.
    Type: Application
    Filed: March 28, 2008
    Publication date: April 15, 2010
    Applicant: SANTHERA PHARMACEUTICALS (SCHWEIZ) AG
    Inventors: Günther Metz, Holger Deppe, Ulrich Abel, Achim Feurer, Inge Ott, Sonja Nordhoff, Michael Soeberdt, Barbara Hoffmann-Enger, Philipp Weyermann, Hervé Siendt, Christian Rummey, Miroslav Terinek, Marco Henneböhle, Holger Herzner, Cesare Mondadori
  • Multimeric apoprotein agonists
    Patent number: 7566695
    Abstract: The present invention provides multimeric apoprotein agonists. Pharmaceutical compositions which include a multimeric apoprotein agonist and a pharmaceutically acceptable carrier, excipient or diluent are also provided. These pharmaceutical are useful to treat a variety of disorders associated with dyslipidemia.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: July 28, 2009
    Assignee: Pfizer Inc.
    Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz
  • Pharmaceutical compositions of apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
    Patent number: 7312190
    Abstract: The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.
    Type: Grant
    Filed: March 15, 2004
    Date of Patent: December 25, 2007
    Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz, Jean Dufourcq
  • Multimeric Apo A-I agonist compounds
    Patent number: 7307058
    Abstract: The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: December 11, 2007
    Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz, Jean Dufourcq
  • Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
    Patent number: 7273848
    Abstract: The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.
    Type: Grant
    Filed: September 8, 2004
    Date of Patent: September 25, 2007
    Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz
  • Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
    Patent number: 7250407
    Abstract: The invention relates to genetic approaches to supply nucleotide sequences encoding modified forms of the native forms of apolipoprotein A-I (ApoA-I): mature ApoA-I, preproApoA-I and proApoA-I; including native ApoA-I modified to contain ApoA-I agonists, peptides which mimic the activity of ApoA-I; ApoA-I superagonists, peptides which exceed the activity of native ApoA-I; and modified native ApoA-I having one or more amphipathic helices replaced by the nucleotide sequences of one or more ApoA-I agonists; for the treatment of disorders associated with dyslipoproteinemia, including cardiovascular disease, atherosclerosis, restenosis, hyperlipidemia, and other disorders such as septic shock.
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: July 31, 2007
    Assignee: Pfizer Inc.
    Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz, Jean Dufourcq
  • Apolipoprotein A-L agonists and their use to treat dyslipidemic disorders
    Patent number: 7189689
    Abstract: The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: March 13, 2007
    Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz, Jean Dufourcq
  • Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
    Patent number: 7157425
    Abstract: The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: January 2, 2007
    Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz
  • Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
    Patent number: 6900177
    Abstract: The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: May 31, 2005
    Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz
  • Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
    Patent number: 6844327
    Abstract: The invention relates to genetic approaches to supply nucleotide sequences encoding modified forms of the native forms of apolipoprotein A-I (ApoA-I): mature ApoA-I, preproApoA-I and proApoA-I; including native ApoA-I modified to contain ApoA-I agonists, peptides which mimic the activity of ApoA-I; ApoA-I superagonists, peptides which exceed the activity of native ApoA-I; and modified native ApoA-I having one or more amphipathic helices replaced by the nucleotide sequences of one or more ApoA-I agonists; for the treatment of disorders associated with dyslipoproteinemia, including cardiovascular disease, atherosclerosis, restenosis, hyperlipidemia, and other disorders such as septic shock.
    Type: Grant
    Filed: October 29, 2002
    Date of Patent: January 18, 2005
    Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz, Jean Dufourcq
  • Multimeric Apoa-I agonist compounds
    Patent number: 6753313
    Abstract: The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.
    Type: Grant
    Filed: December 1, 1999
    Date of Patent: June 22, 2004
    Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz, Jean Dufourcq
  • Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
    Patent number: 6734169
    Abstract: The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.
    Type: Grant
    Filed: May 25, 2001
    Date of Patent: May 11, 2004
    Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz
  • Multimeric Apo A-I agonist compounds
    Patent number: 6716816
    Abstract: The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.
    Type: Grant
    Filed: December 1, 1999
    Date of Patent: April 6, 2004
    Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz, Jean Dufourcq
  • Method of treating dyslipidemia
    Patent number: 6630450
    Abstract: The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.
    Type: Grant
    Filed: December 1, 1999
    Date of Patent: October 7, 2003
    Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz, Jean Dufourcq
  • Branched multimeric Apo A-I agonist compounds
    Patent number: 6602854
    Abstract: The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.
    Type: Grant
    Filed: December 1, 1999
    Date of Patent: August 5, 2003
    Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz, Jean Dufourcq
  • Apolipoprotein A-I agonist compounds
    Patent number: 6573239
    Abstract: The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.
    Type: Grant
    Filed: December 1, 1999
    Date of Patent: June 3, 2003
    Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz, Jean Dufourcq
  • Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
    Patent number: 6518412
    Abstract: The invention relates to genetic approaches to supply nucleotide sequences encoding modified forms of the native forms of apolipoprotein A-I (ApoA-I): mature ApoA-I, preproApoA-I and proApoA-I; including native ApoA-I modified to contain ApoA-I agonists, peptides which mimic the activity of ApoA-I; ApoA-I superagonists, peptides which exceed the activity of native ApoA-I; and modified native ApoA-I having one or more amphipathic helices replaced by the nucleotide sequences of one or more ApoA-I agonists; for the treatment of disorders associated with dyslipoproteinemia, including cardiovascular disease, atherosclerosis, restenosis, hyperlipidemia, and other disorders such as septic shock.
    Type: Grant
    Filed: September 29, 1997
    Date of Patent: February 11, 2003
    Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz, Jean Dufourcq
  • Lipid complexes of APO A-1 agonist compounds
    Patent number: 6376464
    Abstract: The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.
    Type: Grant
    Filed: December 1, 1999
    Date of Patent: April 23, 2002
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz, Jean Dufourcq
  • Method of treating septic shock
    Patent number: 6329341
    Abstract: The present invention provides peptides and petptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.
    Type: Grant
    Filed: December 1, 1999
    Date of Patent: December 11, 2001
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz, Jean Dufourcq